Insulet Corporation $PODD Shares Sold by HB Wealth Management LLC

HB Wealth Management LLC trimmed its stake in shares of Insulet Corporation (NASDAQ:PODD) by 17.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,885 shares of the medical instruments supplier’s stock after selling 395 shares during the quarter. HB Wealth Management LLC’s holdings in Insulet were worth $592,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Janney Montgomery Scott LLC raised its position in shares of Insulet by 784.9% during the 2nd quarter. Janney Montgomery Scott LLC now owns 47,827 shares of the medical instruments supplier’s stock worth $15,026,000 after buying an additional 42,422 shares in the last quarter. V Square Quantitative Management LLC raised its position in shares of Insulet by 5.8% during the 2nd quarter. V Square Quantitative Management LLC now owns 1,930 shares of the medical instruments supplier’s stock worth $606,000 after buying an additional 106 shares in the last quarter. Western Financial Corp CA bought a new stake in shares of Insulet during the 2nd quarter worth about $1,064,000. Patton Fund Management Inc. bought a new stake in shares of Insulet during the 2nd quarter worth about $265,000. Finally, Novem Group bought a new stake in shares of Insulet during the 2nd quarter worth about $1,045,000.

Insulet Stock Performance

PODD stock opened at $309.11 on Friday. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $21.76 billion, a price-to-earnings ratio of 93.95, a P/E/G ratio of 2.57 and a beta of 1.40. Insulet Corporation has a 12 month low of $225.37 and a 12 month high of $353.50. The firm has a 50 day moving average of $321.34 and a two-hundred day moving average of $298.76.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, topping the consensus estimate of $0.92 by $0.25. The company had revenue of $649.10 million during the quarter, compared to the consensus estimate of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company’s revenue for the quarter was up 32.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, equities analysts anticipate that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Insider Activity at Insulet

In other news, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the sale, the senior vice president directly owned 3,890 shares in the company, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Prem Singh sold 687 shares of the business’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the sale, the senior vice president owned 3,456 shares of the company’s stock, valued at $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.39% of the company’s stock.

Analyst Upgrades and Downgrades

PODD has been the topic of a number of recent analyst reports. Citigroup restated a “buy” rating on shares of Insulet in a research report on Tuesday, July 8th. Canaccord Genuity Group boosted their target price on shares of Insulet from $353.00 to $399.00 and gave the stock a “buy” rating in a report on Monday, September 29th. Truist Financial started coverage on shares of Insulet in a report on Monday, June 16th. They issued a “buy” rating and a $365.00 target price on the stock. Royal Bank Of Canada boosted their target price on shares of Insulet from $330.00 to $350.00 and gave the stock an “outperform” rating in a report on Friday, August 8th. Finally, Barclays boosted their target price on shares of Insulet from $266.00 to $300.00 and gave the stock an “equal weight” rating in a report on Thursday, August 21st. Seventeen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $346.83.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.